Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Mesenchymal Stromal Cells (MSC)

The focus of the current MSC Specialized Working Group is to better understand mechanisms through which MSCs could modulate immune responses, identify individual cells belonging to the innate and adaptive immune responses that interact with MSCs and define the molecular…

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more

Join EHA and BSH and receive a discount on your EHA membership fee!

We are pleased to inform that EHA and the British Society of Haematology (BSH) have joined forces and are offering you the possibility of an EHA-BSH Joint Membership.

Read more

In Memoriam Professor Emeritus Michel Symann

Dear Colleagues,

My dear friend Professor Emeritus Michel Symann passed away on April 23, 2023 at the age of 81.

Read more